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Introduction: Lung tumor delineation is frequently performed using 
3D positron emission tomography (PET)/computed tomography 
(CT), particularly in the radiotherapy treatment planning position, 
by generating an internal target volume (ITV) from the slow acquisi-
tion PET. We investigate the dosimetric consequences of stereotactic 
ablative body radiotherapy (SABR) planning on 3D PET/CT in com-
parison with gated (4D) PET/CT.
Methods: In a prospective clinical trial, patients with lung metasta-
ses were prescribed 26 Gy single-fraction SABR to the covering iso-
dose. Contemporaneous 3D PET/CT and 4D PET/CT was performed 
in the same patient position. An ITV was generated from each data 
set, with the planning target volume (PTV) being a 5-mm isotro-
pic expansion. Dosimetric parameters from the SABR plan derived 
using the 3D volumes were evaluated against the same plan applied 
to 4D volumes.
Results: Ten lung targets were evaluated. All 3D plans were success-
fully optimized to cover 99% of the PTV by the 26 Gy prescription. In 
all cases, the calculated dose delivered to the 4D target was less than 
the expected dose to the PTV based on 3D planning. Coverage of the 
4D-PTV by the prescription isodose ranged from 74.48% to 98.58% 
(mean of 90.05%). The minimum dose to the 4D-ITV derived by 
the 3D treatment plan (mean = 93.11%) was significantly lower than 
the expected dose to ITV based on 3D PET/CT calculation (mean = 
111.28%), p < 0.01. In all but one case, the planned prescription dose 
did not cover the 4D-PET/CT derived ITV.
Conclusions: Target delineation using 3D PET/CT without addi-
tional respiratory compensation techniques results in significant tar-
get underdosing in the context of SABR.
Key Words: Stereotactic ablative body radiotherapy, Positron emis-
sion tomography, Lung cancer, Oligometastases, Four-dimensional, 
Respiratory gated, Radiation therapy margins.
(J Thorac Oncol. 2015;10: 1112–1115)
Respiratory motion is known to introduce a potential risk of inadequate target coverage in the setting of radiotherapy 
for lung tumors. To mitigate this risk, the use of respiratory-
gated (4D) computed tomography (CT) is increasingly preva-
lent to account for respiratory-induced tumor excursion.1 More 
recently, the use of simulation positron emission tomography 
(PET)/CT in the radiotherapy treatment planning position has 
enabled more accurate delineation of thoracic malignancies 
by overcoming registration errors normally introduced when 
planning using a simulation CT scan fused to a separately cap-
tured diagnostic.2 In many centers, PET/CT scans acquired in 
the radiotherapy treatment position are performed without 
compensating for respiration on the assumption that this slow 
acquisition scan, which can take up to 30 minutes to acquire, 
may adequately capture respiratory induced tumor excursion 
across many breathing cycles. However, the intensity of the 
PET signal varies according to the ventilatory pattern and 
may underestimate the range of tumor excursion depending 
on patient specific breathing patterns.3
Stereotactic ablative body radiotherapy (SABR) is a 
high precision radiotherapy technique characterized by sharp 
dose gradients and tight tumor margins. In the context of 
SABR, it is plausible that inaccurate target delineation may 
result in significant reduction in dose delivered to the tumor. 
The hypothesis of this study is that target delineation using 
slow acquisition 3D PET/CT when compared with 4D PET/
CT will result in an increased risk of geographic miss using 
SABR. The primary aim is to assess the dosimetric impact 
of radiotherapy planning using conventional 3D PET/CT in 
comparison with 4D PET/CT.
MATERIALS AND METHODS
As part of an independent ethics board approved pro-
spective clinical trial (Universal Trial Number U1111-1145-
0751), consecutive patients with peripheral lung metastasis 
were enrolled. Eligibility was defined as patients with no more 
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than 1 to 2 18F-FDG-PET avid pulmonary metastases with 
a maximum tumor diameter of less than 5 cm. Tumors were 
peripherally located beyond the exclusion envelope of 2 cm 
from central airways as defined by Timmerman et al.4
PET/CT Acquisition
Patients sequentially completed both a standard whole 
body PET/CT and a 4D PET/CT scan in a default radiotherapy 
planning position using the radiotherapy palette and head rest 
with their arms raised. Patients were not given any breath-
ing coaching. All trial-related PET scans were performed on 
a GE-Discovery 690 PET/CT scanner (GE Medical Systems 
Milwaukee, WI). A free-breathing PET/CT scan was acquired 
first and took approximately 20 minutes. Immediately after 
the completion, a 4D-CT scan was acquired centered over 
the lesion of interest. Ventilation was allowed to stabilize 
and recorded using the Varian Real-Time Patient Monitoring 
(RPM) system (Palo Alto, CA). A step and shoot 4D-CT scan 
was performed and followed by a 10-minute list-mode PET 
acquisition while recording the patient breathing trace. The 
GE automatic phase matching software was used to process 
the 4D-PET/CT scan into 10 bins based on a percentage of the 
respiratory cycle (i.e., 0%, 10%, 20%, etc.). A representative 
example of sequential 3D and 4D PET/CT acquisition is given 
in Figure 1. From the respiratory correlated CT data, a maxi-
mum intensity projection (MIP) CT data set was produced 
by the GE motion match software. Using the MIM Maestro 
software (MIM 5.4.4, MIM Software Inc., Cleveland, OH), 
an equivalent PET MIP data set was reconstructed from the 
respiratory correlated PET data.5 This PET (MIP) image dem-
onstrates the maximum PET avidity of each voxel across the 
respiratory cycle. A CT average (AVG) data set was recon-
structed from the 4D-PET/CT data, in which the density of 
each voxel is represented as the average density of that voxel 
across all respiratory phases. All PET and CT data were recon-
structed with a slice thickness of 3.75 mm.
Target Delineation
Image sets were imported in CMS Focal for the purpose 
of target volume and critical structure delineation. A single 
experienced thoracic radiation oncologist (D.L.B.) indepen-
dently delineated both 3D and 4D targets at separate sittings. 
Manual contouring was performed using a protocol found to 
be highly reproducible for target delineation as previously 
published.6 In delineating target volumes, the internal target 
volume (ITV) concept was used. A 3D-ITV was delineated 
using 3D-CT and 3D-PET data sets. For the purposes of plan-
ning, the 3D-PET/CT was assumed to produce a target volume 
inclusive of respiratory motion, because of the long acquisi-
tion time of the PET component. A 4D-ITV was delineated 
using 4D-CT (MIP) and 4D-PET (MIP). Standardized lung 
window/level settings (1700 ± 300) were used for the CT data 
sets. After target delineation, the 3D-CT and 4D-CT (MIP) 
were fused to 4D-PET/CT (AVG). As the 3D and 4D data sets 
were acquired sequentially without patient repositioning, the 
fusion was based on the shared DICOM origin of the data sets 
and verified through visual assessment. After image fusion, 
the 3D-ITVs and 4D-ITVs were copied from their respective 
4D CT-MIP 4D PET-MIP 4D PET/CT-MIP
Free Breathing-CT Free Breathing-PET Free Breathing-PET/CT
FIGURE 1.  The 4D positron emission tomography (PET)/computed tomography (CT) acquisition (above) and 3D PET/CT 
acquisition (below) in a patient with a lower lobe tumor, demonstrating CT images (left), PET images (middle), and coregistered 
PET/CT images (right).
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data sets to the 4D-PET/CT (AVG) for the purpose of treat-
ment planning and dose calculation. A uniform expansion 
of 5 mm was applied to both 3D-ITV and 4D-ITV to cre-
ate the 3D-planning target volume (3D-PTV) and 4D-PTV, 
respectively.
Treatment Planning
Treatment planning was performed using CMS XiO 
(Elekta, Stockholm, Sweden) by a single experienced radia-
tion therapist (B.C.). Treatment plans consisted of 8 to 12 
fields (median 10) as previously described,7 with multi-leaf 
collimator (MLC) apertures adapted to fit the 3D-PTV using 
autoport functionality. Dose was prescribed to the covering 
80% isodose. MLC apertures were individually optimized 
both to achieve target coverage and to maximize dose con-
formity to the PTV. This optimization included use of nega-
tive MLC margins. Dose calculations were performed using 
a Superposition/Convolution calculation algorithm and a 
0.2 cm calculation grid. Beam weightings and MLC apertures 
were optimized to achieve coverage of the 3D-PTV equal to 
D99, 100%.
Once the plan had been optimized to achieve coverage 
of the 3D-PTV, the coverage of the 4D-PTV achieved with 
this plan was evaluated using dose volume histogram analysis. 
The percentage of 4D-PTV enclosed within the prescription 
isodose was recorded, along with the absolute minimum dose 
received by the 4D-PTV and 4D-ITV. Dosimetric coverage 
between 3D and 4D volumes was compared using two-sided 
paired t-tests. The minimum biological effective dose (BED)8 
achieved at the periphery of the PTV was calculated based on 
the 4D volumes using an alpha/beta ratio of 10 Gy and com-
pared with the expected BED
10 Gy
 of 94 Gy.
RESULTS
Ten peripheral lung metastases in eight patients were 
planned for a single fraction 26 Gy of SABR. Distribution of 
targets was as follows; one target in the right upper lobe, two 
in the left upper lobe, two in the right middle lobe, two targets 
in the right lower lobe, and two in the left lower lobe. The right 
middle lobe tumors were grouped with the right upper lobe 
tumors for the remainder of the analysis. The absolute volumes 
of the 3D-PTV (mean 16.85 cc) and 4D-PTV (mean 18.43 cc) 
were not significantly different, p is equal to 0.51, Table 1.
In producing plans optimized to the 3D-PTV, all plans 
were successfully optimized to achieve the objective of the 
dose to 99% of the PTV (D99), 100%. Coverage of the 4D-PTV 
by the 3D derived treatment plan was significantly lower, with 
a mean of 90.05% (range 74.48–98.58%) of the 4D-PTV 
enclosed within the prescription isodose. The resultant mini-
mum BED
10 Gy
 at the periphery of the 4D PTV volume was a 
mean of 57.61 Gy (range 33.29–71.70 Gy). The percentage of 
4D-PTV enclosed within the prescription isodose, minimum 
4D-PTV dose, and resultant BED
10 Gy
 for each case is reported 
in Table 2. Coverage of the 4D-PTV was dependent upon the 
anatomical location of the target within the lung. Target cover-
age with the prescription dose was significantly less in lower 
lobe tumors (mean = 83.92%) when compared with upper 
lobe (mean = 96.18%), p is equal to 0.01.
TABLE 1.   Absolute Volume (cc) of 3D-PTV and 4D-PTV
3D-PTV (cc) 4D-PTV (cc) Target Location
1 3.98 5.33 RLL
2 52.04 72.04 LLL
3 19.18 15.8 RML
4 14.66 14.02 RML
5 12.18 9.87 LUL
6 11.30 14.2 RLL
7 18.48 15.14 LLL
8 4.94 6.29 LLL
9 25.63 25.59 LUL
10 6.12 6.01 RUL
PTV, planning target volume; RLL, right lower lobe; LLL, left lower lobe; RML, 
right middle lobe; LUL, left upper lobe; RUL, right upper lobe.
TABLE 2.   %PTV enclosed within Prescription Isodose
Case
3D-PTV 
Covered by 
26 Gy (%)
4D-PTV 
Covered by 
26 Gy (%)
4D PTV 
Min Dose 
(Gy)
BED
10Gy
  
at Periphery 
of PTV (Gy)
Anatomical 
Lobe
1 99 82.66 15.89 41.14 Lower
2 99 90.22 18.42 52.35 Lower
3 99 97.8 15.17 69.93 Upper
4 99 98.58 21.16 65.93 Upper
5 99 96.54 22.24 71.70 Upper
6 99 80.03 13.92 33.30 Lower
7 99 92.25 20.64 63.24 Lower
8 99 74.48 16.37 43.17 Lower
9 99 95.74 22.03 70.56 Upper
10 99 92.24 20.95 64.84 Upper
All plans failed to meet D99 = 100% for 4D-PTV when applying the 3D derived 
treatment plan.
BED, biological effective dose; PTV, planning target volume.
TABLE 3.  Minimum Dose to the ITV from the Treatment 
Plan, Comparing 3D PET/CT and 4D PET/CT Calculations
Case
Minimum 
3D-ITV 
(%)
Minimum 
4D-ITV 
(%)
Anatomical 
Lobe
1 115.5 86.92 Lower
2 107.8 91.76 Lower
3 115.3 98.51 Upper
4 110.6 99.55 Upper
5 111.1 99.34 Upper
6 111.4 78.42 Lower
7 109.7 93.13 Lower
8 109.7 83.63 Lower
9 109.0 98.69 Upper
10 112.7 101.19 Upper
In all but one case, the 4D-ITV received less than the prescription isodose.
PET/CT, positron emission tomography/computed tomography; ITV, internal target 
volume.
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In addition to coverage of the PTV, the minimum dose 
received by both the 3D-PET/CT and 4D-PET/CT derived ITVs 
was recorded, with results reported in Table 3. The minimum 
dose to the 4D-ITV (mean = 93.11%) derived by the 3D treat-
ment plan was uniformly lower than the expected dose to ITV 
based on 3D PET/CT calculation (mean = 111.28%), p < 0.01. 
Similar to the PTV coverage, the minimum dose to ITV was 
significantly less in lower lobe tumors (mean = 86.77%) when 
compared with upper lobe (mean = 99.46%), p is equal to 0.01.
DISCUSSION
In this study, we demonstrate that the delineation of pul-
monary targets using 3D PET/CT imaging results in significant 
risk of marginal miss. In all cases, the calculated dose delivered 
was less than the expected dose to the PTV when compared 
with target volumes generated from 4D PET/CT, resulting in 
significantly less than expected biological dose at the target 
periphery. When applying 3D-PET/CT based treatment plan to 
4D-PET/CT volumes, all plans failed to meet the D99 equal to 
100% PTV coverage objective. A similar but less marked dosi-
metric impact was observed for the ITV. In all but one case, 
the prescription dose from the 3D derived treatment plan pre-
scription did not cover the ITV derived from the 4D-PET/CT. 
This phenomenon was largely observed in tumors situated in 
the lower lobes, which are more prone to ventilation-induced 
motion error, and in contrast, the upper lobe tumors maintained 
an average minimum dose of 99.46% to the ITV.
Simulation 3D PET/CT in the radiotherapy treatment 
position is an attractive proposition for the delineation of lung 
tumors because of the minimization of registration errors across 
functional and anatomical data sets. When defining target vol-
umes the information obtained from the two imaging modalities 
provides complementary information about both tumor struc-
ture (CT) and physiology (PET).9 Despite the fact that 3D PET/
CT acquisition inherently covers many more respiratory cycles 
than is routinely captured with conventional respiratory-gated 
radiotherapy simulation techniques, our study demonstrates 
that target coverage is inadequate for SABR when delineating 
using 3D techniques. This is particularly evident for lower lobe 
tumors. Our findings are consistent with previous phantom3,5 
and clinical studies investigating the impact of target delinea-
tion using 3D PET/CT when compared with 4DCT10,11 or 4D 
PET/CT12–16 acquisition techniques. Importantly, in this study, 
we demonstrate that these differences in delineation result in 
significant dosimetric consequences in the context of radiother-
apy treatment delivery.
There are several limitations of this study. The use of 
4D-PET/CT over conventional 4DCT in SABR planning is 
not directly compared in this study. However, 4D-PET/CT 
may be an attractive modality as it is a single-acquisition 
technique that provides respiratory compensated target defi-
nition for radiotherapy planning, functional tumor informa-
tion, and screening of occult distant widespread metastases. 
This study only includes patients with lung metastases, and 
therefore, these findings may not be directly extrapolated to 
patients with primary lung cancer and preexisting lung dis-
ease, which might impact on tumor mobility. We recommend 
that 3D-PET/CT is not used to define the target volume in 
lung SABR because of the significant risk of geographic miss.
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